The COSMIQ Blog
Articles tagged “dna damage response” · Clear filter
CStone and Kimia Plan Early Clinical Study of Solid-Tumor Candidate
CStone Pharmaceuticals says it will lead Phase I development in mainland China and Australia for a Kimia Therapeutics drug candidate aimed at a DNA damage response pathway. The announcement describes an early-stage collaboration, not evidence of patient benefit.
Learn anything, free.
COSMIQ is a free, voice-driven AI tutor for every learner. No credit card, ever.
Start learning free →